Assert-IQ vs Cardio-TriTest

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

Cardio-TriTest

by Cardio-Phoenix

AI Verdict

Assert-IQ focuses on long-term, continuous cardiac monitoring for arrhythmia detection through a minimally invasive insertable device, ideal for ongoing patient management. Cardio-TriTest, however, is a non-invasive, 3-in-1 diagnostic device designed for comprehensive, point-in-time cardiovascular disease detection in a clinical setting. While both leverage AI in cardiology, their primary functions address different stages and types of cardiac care.

Choose Assert-IQ if…

Choose Assert-IQ if your patient requires long-term, continuous cardiac monitoring (up to 6 years) for the diagnosis and management of suspected infrequent arrhythmias that may not be captured by shorter-term monitoring methods. This tool is ideal for remote monitoring and provides proactive alerts for clinicians, enabling timely intervention for sporadic heart rhythm disorders.

View Assert-IQ →

Choose Cardio-TriTest if…

Choose Cardio-TriTest if you need a comprehensive, non-invasive, multi-modal cardiovascular assessment for earlier disease detection in a primary care or clinical setting. This 3-in-1 device (ECG, PCG, MCG) offers synchronized bio-signal acquisition and AI-powered analysis to visually correlate heart signals, providing a robust initial diagnostic evaluation.

View Cardio-TriTest →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	Cardio-TriTest
Deployment	Subcutaneously implanted device with mobile app connectivity	On-premise (device)
FDA Status	Cleared AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Assert-IQ

Assert-IQ, despite requiring a minimally invasive insertion, offers long-term, continuous, and remote monitoring with a patient activator for symptom logging, providing convenience for patients over extended periods. This contrasts with Cardio-TriTest, which, while non-invasive, requires dedicated clinical visits for each diagnostic session. Assert-IQ's cloud-based platform also facilitates remote data access for clinicians.

Clinical Value

Assert-IQ

Assert-IQ provides unparalleled long-term continuous cardiac monitoring for up to six years, which is critical for diagnosing and managing elusive or intermittent arrhythmias that might be missed by shorter-term or point-in-time diagnostics. Its advanced arrhythmia detection algorithms and proactive clinician alerts offer sustained, in-depth insight into a patient's cardiac rhythm. While Cardio-TriTest offers a comprehensive multi-modal snapshot, Assert-IQ's continuous nature provides a distinct and often more critical type of clinical data for specific conditions.

Pricing & Value

Tie

Both Assert-IQ and Cardio-TriTest employ a 'contact for pricing' model, typical for specialized medical devices, and neither provides transparent pricing details or options for a free trial. Without specific cost information or published value-based outcomes, it is impossible to definitively determine which tool offers superior pricing or overall value.

Enterprise Readiness

Assert-IQ

Assert-IQ is backed by Abbott Medical, a global healthcare giant, and is explicitly targeted at 'Large health systems, hospitals, cardiology clinics,' indicating a robust understanding of enterprise needs. Its hybrid deployment model and data export capabilities further demonstrate its suitability for integration into complex healthcare IT environments. Cardio-TriTest, from a smaller company, appears to be a device-based solution with less explicit enterprise-level integration features mentioned.

Innovation

Tie

Assert-IQ demonstrates innovation through its extended monitoring duration of up to six years and its comprehensive remote monitoring capabilities for arrhythmia detection. Cardio-TriTest, on the other hand, innovates by combining three distinct bio-signals (ECG, PCG, and MCG) with AI-powered synchronization for earlier and more comprehensive cardiovascular disease detection. Both tools present significant and distinct technological advancements in their respective areas of cardiac diagnostics.

Support & Docs

Assert-IQ

While specific details on support and documentation are not provided for either tool in the structured facts, Assert-IQ benefits from being a product of Abbott Medical, a large, established global corporation. Companies of this scale typically offer extensive customer support, comprehensive training programs, and robust documentation for their medical devices, which is a significant advantage over a smaller, specialized company.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	Cardio-TriTest
Name	Assert-IQ	Cardio-TriTest
Company	Abbott Medical	Cardio-Phoenix Inc.
Description	The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders.	Cardio-TriTest v6.5 by Cardio-Phoenix Inc. is an AI-powered 3-in-1 diagnostic device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection in primary care.
Key Features	Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission, Secure cloud-based data platform, Remote monitoring capabilities, Proactive clinician alerts, Patient activator for symptom logging, Minimally invasive insertion	3-in-1 diagnostic device (ECG, PCG, MCG), 12-Lead Electrocardiograph (ECG), 4 Lead Phonocardiograph (PCG), 4 Lead Mechanocardiograph (MCG), Synchronized bio-signal acquisition, Visual correlation of heart bio-signals, AI-powered analysis for heart disease detection, Non-invasive test procedure

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and Cardio-TriTest.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do Assert-IQ and Cardio-TriTest integrate into existing clinical workflows for patient diagnosis and management?

Assert-IQ is designed for long-term, continuous remote monitoring of arrhythmias, fitting into ongoing patient management after a minimally invasive insertion. It provides proactive clinician alerts and remote programmability to optimize workflow and reduce in-clinic follow-ups. Cardio-TriTest is a non-invasive, device-based diagnostic test performed in a clinical setting, offering immediate, synchronized bio-signal data for comprehensive cardiovascular disease detection, making it suitable for initial diagnostic workups, especially in primary care.

What is the depth of EHR integration for each tool, particularly for automated data transfer and clinician access?

Assert-IQ utilizes a secure cloud-based data platform and offers data export capabilities, but does not explicitly mention direct EHR integration via API. Clinicians access data through the Merlin.net Patient Care Network, which can be remotely programmed. Cardio-TriTest is a device-based system that generates a structured report with diagnostic findings, and while results can be easily shared, explicit details on automated EHR integration or API availability are not provided in the given information.

What are the key differences in diagnostic capabilities and accuracy for detecting various cardiac conditions?

Assert-IQ focuses on advanced arrhythmia detection algorithms for long-term continuous monitoring of suspected heart rhythm disorders, including AF, bradycardia, tachycardia, and sinus pauses, leveraging AI to reduce false positives while maintaining high sensitivity. Cardio-TriTest is an AI-powered 3-in-1 device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection, aiming to provide echo-equivalent insights for conditions like heart failure and valvular diseases.

For which specific cardiology sub-specialties or patient populations is each tool best suited?

Assert-IQ is best suited for cardiologists and internal medicine specialists managing patients with suspected or diagnosed heart rhythm disorders requiring long-term, continuous monitoring, such as those with unexplained symptoms or at risk for AF. Cardio-TriTest is designed for cardiologists, family medicine, and internal medicine, particularly for primary care settings, to aid in broader, earlier detection of cardiovascular diseases through a non-invasive diagnostic test.

What is the expected learning curve for clinicians and staff, and how quickly can a practice realize value from each system?

Assert-IQ involves a minimally invasive insertion procedure, requiring training for the procedure itself, but its remote monitoring and AI-driven data reduction aim to streamline clinician review and provide long-term value over its multi-year battery life. Cardio-TriTest is a non-invasive test procedure that integrates into existing ECG workflows, suggesting a potentially quicker learning curve for test administration and offering immediate diagnostic results for rapid clinical decision-making and time-to-value.

What are the considerations for multi-site rollout, and are customer references available to assess real-world performance?

Assert-IQ targets large health systems, hospitals, and cardiology clinics, and its cloud-based platform with remote monitoring capabilities is well-suited for multi-site deployments, with clinical evidence and publications available. Cardio-TriTest's device-based deployment suggests that multi-site rollout would involve deploying individual devices to each clinical setting, and the provided information does not specify the availability of customer references.